Alzheimer's Brain Changes Detected Seven Years Before Plaques Appear on Scans

Alzheimer's disease is notoriously difficult to treat, partly because it is typically detected only after substantial brain damage has already accumulated. A major new study from the University of Oslo, published in Nature Neuroscience, challenges the assumption that amyloid plaque detection represents the earliest identifiable sign of the disease — and pushes that timeline back by at least seven years.

The research team followed cognitively healthy older adults over nearly two decades, collecting regular MRI brain scans throughout. This unusually long observation window allowed them to identify which participants eventually showed amyloid plaque buildup on PET scans, then look back at their earlier MRI data to search for preceding structural changes. Participants who later developed detectable plaques showed measurable differences in brain structure years before those plaques appeared.

The core finding is that structural brain changes — detectable with conventional MRI — precede the first signs of amyloid plaque accumulation by more than seven years. Since plaque buildup itself is already considered an early, pre-symptomatic phase occurring years before cognitive decline, this extends the detectable disease window dramatically. Lead researcher James Roe described it as the earliest imaging signal for Alzheimer's identified to date.

For brain health and longevity science, the implications are significant. Earlier detection means a longer potential window for lifestyle, pharmacological, or preventive interventions before irreversible neurodegeneration takes hold. It also suggests that current PET-based screening may be missing a critical early phase of disease biology.

Important caveats remain. The article does not fully detail what specific structural MRI changes were observed, the sample size, or how reliably these changes predict eventual Alzheimer's diagnosis. Whether these early structural shifts are specific to Alzheimer's or reflect broader aging-related vulnerability also needs clarification. Replication in larger, more diverse cohorts will be essential before clinical screening protocols are revised.